Colgate-Palmolive Company (CL)

Rating: HOLD

HOLD (5-tier) · quality defensive · conviction: medium

EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).

Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-26. Each chart below sits with the part of the thesis it evidences.

General research for a skeptical institutional reader. Not personalised investment advice; no position sizing or trade instructions. Figures as of the analysis date; verify before acting.

Investment Committee Summary

📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies -3% vs spot
• Monte Carlo median implies -13% vs spot
• DCF fair value implies -23% vs spot
• Bear case (Structural — Private-Label / Brand Erosion) downside is -55% vs spot
• Net: reward/risk of 0.3× is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Investment Thesis

At $91.68 (26 June 2026) Colgate-Palmolive trades at roughly 23.8x forward earnings against a household-staples peer median of 15.1x. The market is paying a wide premium for defensive, pricing-led organic growth and the belief that brand equity in oral care is durable. The engine is less convinced: the DCF anchor sits at $73.88, peer-multiple triangulation implies $57.61 to $58.40, and Monte Carlo puts only a 40% probability on fair value exceeding spot. The probability-weighted target of $92.64 lands within 1% of the price only because a 34% base case at $98.82 and 28% of combined re-rate paths offset a 20% structural brand-erosion scenario at $42.98. Hence HOLD: the premium is fully paid, and no anchor except the scenario blend supports the current multiple. The most damaging risk is private-label erosion compressing volumes, margin and the multiple simultaneously — a path on which the target sits below the 52-week low of $73.64.

The dashboard below is the whole argument on one page: spot ($95) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The structural bear case carries 20% weight and works like this: four years of pricing above volume have pushed price gaps against private label to historically wide levels in oral care, home care and pet nutrition. Retailers, squeezed themselves, expand own-label shelf space and demand promotional funding back. Volumes turn negative, pricing power is exhausted, and the operating margin compresses toward 14.5% as reinvestment rises. Once organic growth is visibly volume-negative, the defensive premium inverts: a 23.8x forward multiple de-rates to the mid-teens where cheaper peers already trade. Earnings decline and multiple compression compound, producing a $42.98 target — below the 52-week low. Nothing in this chain requires a recession; it requires only that the consumer keeps trading down.

Key Debate

P/E Multiple explains 55% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q1): management +0.36 vs analyst floor +0.00 → delta +0.36 (n=19 mgmt / 11 Q&A; 44th pctile across the S&P book, z -0.2).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 1000 articles): avg ticker sentiment +0.20 (bullish 24% / bearish 2%)

Scenario Analysis

The tree runs from a structural 'Structural — Private-Label / Brand Erosion' downside ($43) to a 'Bull — Defensive Re-Rate' bull case ($148); the probability-weighted blend (PWEV $92) is -3% versus spot.

Scenario rationale — what each probability buys (the driver path behind every target):

• Structural — Private-Label / Brand Erosion (20%, $43). Structural impairment — private-label / brand erosion: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 42.98; probability: 0.2.
• Consumer / Input Recession (18%, $76). Cyclical downturn — branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail) weakens for 1–2 years before normalising. Drivers — implied_target: 76.37; probability: 0.18.
• Base — Pricing-Led Organic Growth (34%, $98). Mid-cycle — normalised branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail); disciplined capital allocation; steady returns. Drivers — implied_target: 98.82; probability: 0.34.
• Growth — Premium Innovation + EM (20%, $126). Upside — premium innovation + emerging markets lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 124.78; probability: 0.2.
• Bull — Defensive Re-Rate (8%, $148). Upside tail — sustained tight conditions or a structural re-rate on premium innovation + emerging markets. Drivers — implied_target: 146.75; probability: 0.08.

Valuation Triangulation

Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Rating vs blend — the key debate. The rating tracks the multiple-discipline fair value (Monte Carlo $82 + scenario PWEV $92, ≈ spot); the weighted blend $79 (-17%) sits below it because the cash-flow DCF ($73) is materially more conservative than the market multiple. Whether the current multiple is justified is the central question for this name — and the principal downside risk to the rating.

Monte Carlo — the distribution, not a point

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $82 and 37% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (55% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 7.5%, 20x terminal FCF multiple → $73. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median forward multiple (P/E 15.13x) implies $58. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.

Across all anchors the spread is 48% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Consumer Staples — Household

This name sits in the Consumer Staples — Household as a household_personal. branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail) Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: PG (household_personal) · CL (household_personal) · KVUE (household_personal) · KMB (household_personal) · EL (household_personal) · CHD (household_personal) · CLX (household_personal)

Mapping note: name-level 'Structural — Private-Label / Brand Erosion' (20%) + 'Consumer / Input Recession' (18%) map to cluster Structural — Private-Label / Brand Erosion (38%); name-level 'Growth — Premium Innovation + EM' (20%) + 'Bull — Defensive Re-Rate' (8%) map to cluster Upside — Premium Innovation / EM (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Structural — Private-Label / Brand Erosion () — this name implies 38% vs the cluster house view of 38% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The staples_household cycle is the shared macro driver. Driver — branded HPC pricing power + organic volume + input costs Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 3% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 7.5% · Σ PV(FCF) $14B + PV(terminal) $52B = EV $65B; + net cash → equity $59B ÷ diluted shares 0.80B = $73/share (exit-multiple terminal).

• Gordon (perpetuity-growth) terminal at 2.5% → $75/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 18% vs WACC 8% → above WACC — the build is value-creative.

Peer set

Peer-median fwd P/E → $58; EV/Rev → $57.

Weighted fair-value math

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Household & Personal Care multiple (AI re-rating) (base 24x)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 0.7% of revenue; cash conversion (OCF/NI) 197% — cash-backed.

Catalyst Calendar

• 2026-07-31 (~23d) — Quarterly earnings — est. EPS $0.95 (AV EARNINGS_CALENDAR)
• 2026-10-30 (~114d) — Hill's Pet Nutrition capacity / growth update (authored)
• 2027-01-30 (~206d) — FY2026 results + FY2027 organic-growth and gross-margin guidance (authored)
• 2027-02-18 (~225d) — Investor update on emerging-market volume and pricing (authored)

Forecast Track Record

• EPS surprise: beat 100.0% of the last 8 quarters; average surprise +3.7%.

Competitive Moat

Wide moat. Colgate's oral-care share (global toothpaste leadership) and pet nutrition (Hill's) give it a genuinely wide moat: dominant category share, dentist-recommendation reinforcement and EM distribution density. That supports a premium to the staples median, but the falsifiable test is oral-care volume share - if global toothpaste share slips or Hill's growth stalls, the ~24x forward multiple should compress toward the mid-to-high-teens; a wide moat justifies a premium, not any multiple.

Moat sources:

• FACT: global toothpaste market-share leadership (~40%+ in many markets) with dentist-recommendation and habit-driven repeat purchase
• FACT: Hill's Pet Nutrition, a vet-endorsed science-diet brand with recurring, low-elasticity demand and structural growth
• INFERENCE: deep emerging-market distribution density (LatAm, India, Africa) that is very costly for entrants to replicate
• INFERENCE: scale in advertising and retailer bargaining power comparable to PG, above CHD/CLX

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

What the Market Is Pricing In

At the current price, the market pays 23.5× forward EPS, vs the house DCF terminal 20.0×, and a peer median 15.13×. The house DCF sits 23% below spot, so the market is pricing in more than the house case — roughly 2.3pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily event-driven.

Peer Quality & Weighting

Quality-weighted forward P/E: 20.4× (simple median 15.13×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $74–$99, centre $85 (-10% vs spot); spot sits at the 85th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

Reward/risk compares triangulated upside against the probability-weighted bear target, not the extreme tail. Bull case (Bull — Defensive Re-Rate): $148.

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (26.0); Revenue CAGR ±3pp (22.0); Terminal × ±15% (19.0); WACC ±1pp (7.0); Capex intensity ±15% (5.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Source Log

Citation coverage: 13/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.

Load-Bearing Assumptions

DCF: WACC 8%, terminal multiple 20×, FY+5 revenue $25B. Triangulation leans 41% on DCF, 29% on PWEV.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Organic sales growth (company-reported) < 2.0 (2 consecutive prints → staples_household). The base path assumes 4% pricing-led organic growth; the recession path assumes roughly flat. Two prints below the 2% midpoint mean pricing power is fading faster than the base scenario allows.
• Organic volume growth (pp contribution to organic sales) < -1.0 (2 consecutive prints → staples_household). If organic growth is all price while volumes contract more than 1pp for two quarters, the private-label / brand-erosion mechanism is operating: consumers are trading out at the shelf.
• GAAP operating margin < 17.6 (2 consecutive prints → staples_household). Base assumes an 18.4% operating margin; the recession path assumes 16.8%. Two prints below the 17.6% midpoint indicate promotional reinvestment or input costs are eating the pricing benefit.
• Gross margin < 58.5 (2 consecutive prints → staples_household). CL's funding-the-growth model depends on gross margin holding around 60%. Two prints below 58.5% signal pricing giveback or raw-material inflation the productivity programme cannot offset, pressuring the margin path in every scenario.
• FY non-GAAP EPS guidance < 3.67 (single event → staples_household). A guidance cut below $3.67 moves the earnings base from the base scenario (about $3.91 implied EPS) toward the recession path (about $3.43), invalidating the probability weights behind the HOLD.

Fact / Inference / Speculation

• FACT: Spot $95; 52-week range $74–$99; engine rating HOLD; base-case target $93 (-3%). (source: Alpha Vantage 2026-06-26, 8 July 2026)
• INFERENCE: Triangulated FV $79 (-17% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Recommendation: HOLD

Balanced: triangulated fair value $79 (-17% vs spot); the outcome hinges on P/E Multiple. The debate is P/E Multiple — fundamentally a multiple/regime call.

Disclosures & Limitations

This report is for informational and research purposes only. It is not personalised investment advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.

• No suitability assessment has been performed for any individual.
• Market data may be delayed or inaccurate; figures are as of the analysis date.
• Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
• Forecasts are uncertain; past performance is not indicative of future returns.
• The author or publisher may hold positions in securities mentioned.
• Users should verify information against primary sources (company filings) before acting.
• Investing involves risk of loss; there is no guarantee any target price is achieved.
• Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.